Idiopathic Thrombocytopenic Purpura Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major idiopathic thrombocytopenic purpura markets are expected to exhibit a CAGR of 4.15% during 2024-2034.
The idiopathic thrombocytopenic purpura market has been comprehensively analyzed in IMARC's new report titled "Idiopathic Thrombocytopenic Purpura Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Idiopathic thrombocytopenic purpura (ITP) is a blood disorder characterized by low platelet counts, which can cause a variety of symptoms related to abnormal bleeding and bruising. Some of the most common indications include easy bruising, nosebleeds, prolonged bleeding after injury or surgery, bleeding gums, blood in urine or stool, petechiae (small red or purple spots on the skin), etc. In many cases, females with ITP may also experience heavy menstrual bleeding, excessive bleeding during childbirth, or bleeding in the brain, which can be life-threatening. The diagnosis typically involves a thorough medical history, physical examination, and blood tests to assess platelet counts. Various additional procedures, such as a bone marrow biopsy, may be recommended to confirm the prognosis or rule out further conditions. In some cases, several imaging tests are also used to check for bleeding or other complications related to low platelet counts. A diagnosis of ITP is typically made if a person has a platelet count of less than 100,000 per microliter of blood and no other underlying medical conditions that could cause thrombocytopenia.
The increasing prevalence of autoimmune disorders in which the immune system mistakenly attacks and destroys the blood platelets is primarily driving the idiopathic thrombocytopenic purpura market. Besides this, the rising incidence of several associated risk factors, such as viral and bacterial infections, certain medical conditions like lupus and rheumatoid arthritis, blood transfusions, etc., is also propelling the market growth. Furthermore, the widespread adoption of corticosteroids as a first-line treatment since they can rapidly improve platelet counts by suppressing the immune response that destroys platelets is creating a positive outlook for the market. Apart from this, the inflating demand for thrombopoietin receptor agonists, including romiplostim and eltrombopag, for increasing platelet counts in patients with chronic ITP who have not responded to other treatments is acting as another significant growth-inducing factor. Additionally, numerous key players are exploring the use of biomarkers to predict response to treatment and identify patients who are at risk of developing more severe forms of the disease. This, in turn, is further augmenting the market growth. Moreover, the emerging popularity of platelet growth factors, such as eltrombopag and romiplostim, which can aid in reducing the likelihood of bleeding incidences, is expected to drive the idiopathic thrombocytopenic purpura market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the idiopathic thrombocytopenic purpura market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for idiopathic thrombocytopenic purpura and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the idiopathic thrombocytopenic purpura market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the idiopathic thrombocytopenic purpura market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the idiopathic thrombocytopenic purpura market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current idiopathic thrombocytopenic purpura marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the idiopathic thrombocytopenic purpura market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the idiopathic thrombocytopenic purpura market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the idiopathic thrombocytopenic purpura market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of idiopathic thrombocytopenic purpura across the seven major markets?
What is the number of prevalent cases (2018-2034) of idiopathic thrombocytopenic purpura by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of idiopathic thrombocytopenic purpura by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with idiopathic thrombocytopenic purpura across the seven major markets?
What is the size of the idiopathic thrombocytopenic purpura patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of idiopathic thrombocytopenic purpura?
What will be the growth rate of patients across the seven major markets?
Idiopathic Thrombocytopenic Purpura: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for idiopathic thrombocytopenic purpura drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the idiopathic thrombocytopenic purpura market?
What are the key regulatory events related to the idiopathic thrombocytopenic purpura market?
What is the structure of clinical trial landscape by status related to the idiopathic thrombocytopenic purpura market?
What is the structure of clinical trial landscape by phase related to the idiopathic thrombocytopenic purpura market?
What is the structure of clinical trial landscape by route of administration related to the idiopathic thrombocytopenic purpura market?
The idiopathic thrombocytopenic purpura market has been comprehensively analyzed in IMARC's new report titled "Idiopathic Thrombocytopenic Purpura Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Idiopathic thrombocytopenic purpura (ITP) is a blood disorder characterized by low platelet counts, which can cause a variety of symptoms related to abnormal bleeding and bruising. Some of the most common indications include easy bruising, nosebleeds, prolonged bleeding after injury or surgery, bleeding gums, blood in urine or stool, petechiae (small red or purple spots on the skin), etc. In many cases, females with ITP may also experience heavy menstrual bleeding, excessive bleeding during childbirth, or bleeding in the brain, which can be life-threatening. The diagnosis typically involves a thorough medical history, physical examination, and blood tests to assess platelet counts. Various additional procedures, such as a bone marrow biopsy, may be recommended to confirm the prognosis or rule out further conditions. In some cases, several imaging tests are also used to check for bleeding or other complications related to low platelet counts. A diagnosis of ITP is typically made if a person has a platelet count of less than 100,000 per microliter of blood and no other underlying medical conditions that could cause thrombocytopenia.
The increasing prevalence of autoimmune disorders in which the immune system mistakenly attacks and destroys the blood platelets is primarily driving the idiopathic thrombocytopenic purpura market. Besides this, the rising incidence of several associated risk factors, such as viral and bacterial infections, certain medical conditions like lupus and rheumatoid arthritis, blood transfusions, etc., is also propelling the market growth. Furthermore, the widespread adoption of corticosteroids as a first-line treatment since they can rapidly improve platelet counts by suppressing the immune response that destroys platelets is creating a positive outlook for the market. Apart from this, the inflating demand for thrombopoietin receptor agonists, including romiplostim and eltrombopag, for increasing platelet counts in patients with chronic ITP who have not responded to other treatments is acting as another significant growth-inducing factor. Additionally, numerous key players are exploring the use of biomarkers to predict response to treatment and identify patients who are at risk of developing more severe forms of the disease. This, in turn, is further augmenting the market growth. Moreover, the emerging popularity of platelet growth factors, such as eltrombopag and romiplostim, which can aid in reducing the likelihood of bleeding incidences, is expected to drive the idiopathic thrombocytopenic purpura market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the idiopathic thrombocytopenic purpura market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for idiopathic thrombocytopenic purpura and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the idiopathic thrombocytopenic purpura market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the idiopathic thrombocytopenic purpura market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the idiopathic thrombocytopenic purpura market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current idiopathic thrombocytopenic purpura marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the idiopathic thrombocytopenic purpura market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the idiopathic thrombocytopenic purpura market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the idiopathic thrombocytopenic purpura market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of idiopathic thrombocytopenic purpura across the seven major markets?
What is the number of prevalent cases (2018-2034) of idiopathic thrombocytopenic purpura by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of idiopathic thrombocytopenic purpura by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with idiopathic thrombocytopenic purpura across the seven major markets?
What is the size of the idiopathic thrombocytopenic purpura patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of idiopathic thrombocytopenic purpura?
What will be the growth rate of patients across the seven major markets?
Idiopathic Thrombocytopenic Purpura: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for idiopathic thrombocytopenic purpura drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the idiopathic thrombocytopenic purpura market?
What are the key regulatory events related to the idiopathic thrombocytopenic purpura market?
What is the structure of clinical trial landscape by status related to the idiopathic thrombocytopenic purpura market?
What is the structure of clinical trial landscape by phase related to the idiopathic thrombocytopenic purpura market?
What is the structure of clinical trial landscape by route of administration related to the idiopathic thrombocytopenic purpura market?
?1 Preface
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 IDIOPATHIC THROMBOCYTOPENIC PURPURA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 IDIOPATHIC THROMBOCYTOPENIC PURPURA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 IDIOPATHIC THROMBOCYTOPENIC PURPURA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 IDIOPATHIC THROMBOCYTOPENIC PURPURA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 IDIOPATHIC THROMBOCYTOPENIC PURPURA - UNMET NEEDS
10 IDIOPATHIC THROMBOCYTOPENIC PURPURA - KEY ENDPOINTS OF TREATMENT
11 IDIOPATHIC THROMBOCYTOPENIC PURPURA - MARKETED PRODUCTS
11.1 List of Idiopathic Thrombocytopenic Purpura Marketed Drugs Across the Top 7 Markets
11.1.1 Carimune NF (Immune globulin) - CSL Behring
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Cuvitru (Immune globulin) - Takeda
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Tavalisse (Fostamatinib) - Rigel Pharmaceuticals
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Promacta (Eltrombopag) - Novartis
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Nplate (Romiplostim) - Amgen
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 IDIOPATHIC THROMBOCYTOPENIC PURPURA - PIPELINE DRUGS
12.1 List of Idiopathic Thrombocytopenic Purpura Pipeline Drugs Across the Top 7 Markets
12.1.1 GNR 069 - GENERIUM Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 PRN 1008 - Principia Biopharma
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Rozanolixizumab - UCB
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Ianalumab - MorphoSys/Novartis
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 BT 595 - Biotest
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. IDIOPATHIC THROMBOCYTOPENIC PURPURA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. IDIOPATHIC THROMBOCYTOPENIC PURPURA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 IDIOPATHIC THROMBOCYTOPENIC PURPURA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Idiopathic Thrombocytopenic Purpura - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Idiopathic Thrombocytopenic Purpura - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Idiopathic Thrombocytopenic Purpura - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Idiopathic Thrombocytopenic Purpura - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Idiopathic Thrombocytopenic Purpura - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Idiopathic Thrombocytopenic Purpura - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Idiopathic Thrombocytopenic Purpura - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Idiopathic Thrombocytopenic Purpura - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Idiopathic Thrombocytopenic Purpura - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Idiopathic Thrombocytopenic Purpura - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Idiopathic Thrombocytopenic Purpura - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Idiopathic Thrombocytopenic Purpura - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Idiopathic Thrombocytopenic Purpura - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Idiopathic Thrombocytopenic Purpura - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Idiopathic Thrombocytopenic Purpura - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Idiopathic Thrombocytopenic Purpura - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Idiopathic Thrombocytopenic Purpura - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Idiopathic Thrombocytopenic Purpura - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Idiopathic Thrombocytopenic Purpura - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Idiopathic Thrombocytopenic Purpura - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Idiopathic Thrombocytopenic Purpura - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Idiopathic Thrombocytopenic Purpura - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Idiopathic Thrombocytopenic Purpura - Access and Reimbursement Overview
16 IDIOPATHIC THROMBOCYTOPENIC PURPURA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 IDIOPATHIC THROMBOCYTOPENIC PURPURA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 IDIOPATHIC THROMBOCYTOPENIC PURPURA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 IDIOPATHIC THROMBOCYTOPENIC PURPURA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 IDIOPATHIC THROMBOCYTOPENIC PURPURA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 IDIOPATHIC THROMBOCYTOPENIC PURPURA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 IDIOPATHIC THROMBOCYTOPENIC PURPURA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 IDIOPATHIC THROMBOCYTOPENIC PURPURA - UNMET NEEDS
10 IDIOPATHIC THROMBOCYTOPENIC PURPURA - KEY ENDPOINTS OF TREATMENT
11 IDIOPATHIC THROMBOCYTOPENIC PURPURA - MARKETED PRODUCTS
11.1 List of Idiopathic Thrombocytopenic Purpura Marketed Drugs Across the Top 7 Markets
11.1.1 Carimune NF (Immune globulin) - CSL Behring
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Cuvitru (Immune globulin) - Takeda
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Tavalisse (Fostamatinib) - Rigel Pharmaceuticals
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Promacta (Eltrombopag) - Novartis
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Nplate (Romiplostim) - Amgen
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 IDIOPATHIC THROMBOCYTOPENIC PURPURA - PIPELINE DRUGS
12.1 List of Idiopathic Thrombocytopenic Purpura Pipeline Drugs Across the Top 7 Markets
12.1.1 GNR 069 - GENERIUM Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 PRN 1008 - Principia Biopharma
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Rozanolixizumab - UCB
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Ianalumab - MorphoSys/Novartis
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 BT 595 - Biotest
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. IDIOPATHIC THROMBOCYTOPENIC PURPURA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. IDIOPATHIC THROMBOCYTOPENIC PURPURA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 IDIOPATHIC THROMBOCYTOPENIC PURPURA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Idiopathic Thrombocytopenic Purpura - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Idiopathic Thrombocytopenic Purpura - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Idiopathic Thrombocytopenic Purpura - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Idiopathic Thrombocytopenic Purpura - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Idiopathic Thrombocytopenic Purpura - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Idiopathic Thrombocytopenic Purpura - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Idiopathic Thrombocytopenic Purpura - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Idiopathic Thrombocytopenic Purpura - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Idiopathic Thrombocytopenic Purpura - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Idiopathic Thrombocytopenic Purpura - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Idiopathic Thrombocytopenic Purpura - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Idiopathic Thrombocytopenic Purpura - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Idiopathic Thrombocytopenic Purpura - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Idiopathic Thrombocytopenic Purpura - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Idiopathic Thrombocytopenic Purpura - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Idiopathic Thrombocytopenic Purpura - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Idiopathic Thrombocytopenic Purpura - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Idiopathic Thrombocytopenic Purpura - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Idiopathic Thrombocytopenic Purpura - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Idiopathic Thrombocytopenic Purpura - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Idiopathic Thrombocytopenic Purpura - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Idiopathic Thrombocytopenic Purpura - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Idiopathic Thrombocytopenic Purpura - Access and Reimbursement Overview
16 IDIOPATHIC THROMBOCYTOPENIC PURPURA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 IDIOPATHIC THROMBOCYTOPENIC PURPURA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 IDIOPATHIC THROMBOCYTOPENIC PURPURA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
